Ultragenyx Pharmaceutical (RARE) Revenue (QoQ) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.39% |
| Dec 31, 2025 | 29.60% |
| Sep 30, 2025 | -3.94% |
| Jun 30, 2025 | 19.78% |
| Mar 31, 2025 | -15.58% |
| Dec 31, 2024 | 18.03% |
| Sep 30, 2024 | -5.12% |
| Jun 30, 2024 | 35.09% |
| Mar 31, 2024 | -14.40% |
| Dec 31, 2023 | 29.67% |
| Sep 30, 2023 | -9.47% |
| Jun 30, 2023 | 7.77% |
| Mar 31, 2023 | -2.76% |
| Dec 31, 2022 | 13.94% |
| Sep 30, 2022 | 1.52% |
| Jun 30, 2022 | 11.77% |
| Mar 31, 2022 | -4.14% |
| Dec 31, 2021 | 2.13% |
| Sep 30, 2021 | -6.13% |
| Jun 30, 2021 | -12.50% |
| Mar 31, 2021 | 8.58% |
| Dec 31, 2020 | 12.36% |
| Sep 30, 2020 | 32.02% |
| Jun 30, 2020 | 69.96% |
| Mar 31, 2020 | 2.01% |
| Dec 31, 2019 | 37.96% |
| Sep 30, 2019 | 6.84% |
| Jun 30, 2019 | 32.89% |
| Mar 31, 2019 | 11.75% |
| Dec 31, 2018 | 38.24% |
| Sep 30, 2018 | -8.06% |
| Jun 30, 2018 | 19.83% |
| Mar 31, 2018 | 408.43% |
| Dec 31, 2017 | 960.61% |
| Dec 31, 2016 | -95.50% |
| Sep 30, 2016 | 552.94% |